Ethosomal formulation as a carrier for transdermal delivery

Obstacles[ edit ] Although the skin is a large and logical target for drug delivery, its basic functions limit its utility for this purpose. The skin functions mainly to protect the body from external insults e.

Ethosomal formulation as a carrier for transdermal delivery

From bench to clinical implementation This research article by Dr.

CiteSeerX — Transdermal drug delivery Correspondence to Author:

Nida Akhtar et al. These vesicles are capable of enclosing both hydrophilic and lipophilic drugs. Various preclinical and clinical reports on drugs delivered via ethosomes have been highlighted in this article which suggests that these nanocarriers can be employed for drug targeting via transdermal route.

Ethosomal formulation as a carrier for transdermal delivery

Antimicrobials such as clotrimazole, terbinafine, acyclovir, stavudine, etc have been discussed; these drugs show improved preclinical and clinical results. Anti-inflammatory drugs like thiocolchicoside, curcumin and piroxicam have also depicted with improved anti-inflammatory action.

Several other drugs like alfuzosin hydrochloride, repaglinide, testosterone propionate, enoxaparin, etc also exhibited better penetration, and fluorescence intensity.

Several in vitro and in vivo permeability analysis delineated the enhancement of permeability. In vivo confocal laser scanning microscopy depicted the quantity as well as depth of penetrability via ethosomes.

MATERIALS AND METHODS

Patents on ethosomal transdermal drug delivery have suggested that these nanocarriers can be employed effectively with enhanced penetration and drug diffusion.

Further, safety and toxicity issues have also been raised. Ethosomes have demonstrated no adverse skin reactions in clinical trials with drugs. Post marketing data has also revealed no other adverse reactions, thus, proving them to be safe and effective for drug delivery.

Binary, composite ethosomes, transethosomes are recently developed ethosomal carriers have gained considerable attention as drug delivery vehicles in the past few years and could prove to be an effective carrier system for transdermal delivery.

Ethosomal-based transdermal drug delivery could eventually become an important accession for therapeutics offered to several diseases in the future.Transdermal antigen delivery of ethosomal gel was finally performed on the skin of hair removal mice.

Both solvent and concentration effects on the in vitro release performance of ethosomal gel of carbomer have been confirmed.

Ethosomes: New Prospects in Transdermal Delivery

Ethosomal formulation showed enhanced transdermal flux ± lg/cm 2 h and decreased the lag time of h in comparison to liposomal formulation ( ± lg/cm 2 h; h), ethosomal formulation also showed greater penetration and enhancing effect and highest zone of inhibition in contrast to liposomal formulation and marketed.

skin for transdermal drug delivery. & delivery of large molecules (peptides, protein molecules) is possible. Ethosomal formulation generally contains nontoxic.

classic liposomes are of little or no value as carriers for transdermal drug delivery because they do not deeply penetrate the skin, but rather remain confined to the upper ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar formulation optimization, in-vitro evaluation and preclinical assessment.

Transdermal - Wikipedia

MTX loaded ethosomal carriers also provided an enhanced transdermal flux of +/ microg/cm(2)/h and decreased lag time of h across human cadaver skin. Skin permeation profile of the developed formulation further assessed by confocal laser scanning microscopy (CLSM) revealed an enhanced permeation of Rhodamine Red (RR) loaded.

The aim of present work was to develop, characterisation, of stable ethosomal formulation as a carrier for transdermal delivery of paroxetine hydrochloride. To prepare this ethosome different concentration of soya lecithin and ethanol was taken. Vesicular size, polydispersity index, zeta potential.

Drug Delivery Letters, Volume 8 - Number 3